Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stop and go Strategy in Metastatic Nasopharyngeal Carcinoma
NCT06331845Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 2 trial of capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Fujian Medical University Cancer Hospital. Planned start May 2024; status: not yet recruiting.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06331845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06331845.